June 19, 2026 · Fertility and sterility · DOI: 10.1016/j.fertnstert.2026.06.024

Anti-Mullerian Hormone Rebound and Estradiol Changes in the Study of Women's Health Across the Nation

Listen to this summary

The authors aimed to characterize the prevalence of re-detectable anti-Mullerian hormone (AMH) during the menopause transition and its correlation with other ovarian hormones, particularly estradiol (E2). They found that nearly 54% of women experienced AMH rebound after reaching undetectable levels, with about half of these cases also showing a concurrent increase in E2, suggesting a potential resurgence of ovarian function. Factors such as younger age at the detectable limit of AMH, lower body mass index, and lower follicle-stimulating hormone levels were associated with this rebound, highlighting the variability of ovarian hormone levels during the perimenopausal period.

Laura M Bozzuto, Kelly Acharya, Bethelhem Shiferaw, Laura K Kaizer, Joel S Finkelstein, Genevieve Neal-Perry, Arun Karlamangla, Anthony Morrison, Nanette Santoro, Mary D Sammel

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play